Almost a year after it welcomed its first patient for trial, Elon Musk's neurotechnology company Neuralink has recently closed a new funding round–amounting to US$650 million (£480.44 million) in their latest series E funding round. This funding round–the ninth the company has finished since its founding in 2016–aims to bring Neuralink closer to larger clinical trials–changing ways people who are paralysed to be able to have some form of autonomy in controlling electronic devices for everyday use.
